Want to see SG:P8A full AI Analyst Report?
P8A Stock Chart & Stats
S$0.13
S$0.03(25.00%)
At close: 4:00 PM EDT
S$0.13
S$0.03(25.00%)
Day’s Range― - ―
52-Week RangeS$0.10 - S$0.27
Previous CloseN/A
Volume9.10K
Average Volume (3M)1.15K
Market Cap
S$30.89M
Enterprise Value-S$12.77M
Total Cash (Recent Filing)S$49.83M
Total Debt (Recent Filing)S$4.32M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding267,525,360
10 Day Avg. Volume2,200
30 Day Avg. Volume1,153
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.32
Price to Sales (P/S)0.86
P/FCF Ratio-45.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage reduces solvency and refinancing risk, giving Cordlife greater flexibility while it works through operational losses. The sizable equity base provides financial capacity to maintain its cell-banking infrastructure and pursue recovery without relying heavily on additional debt.
Strong Gross MarginA gross margin near 57% indicates that Cordlife’s underlying collection, processing, testing, and storage services retain meaningful value after direct costs. If revenue stabilizes, this margin structure could support operating leverage and make a return to profitability more achievable.
Losses Are ModeratingThe reduction in losses from prior periods is an important sign that deterioration may be slowing, even though profitability has not returned. Sustained improvement could reduce the need for external funding and allow the company’s recurring storage model to translate into stronger earnings over time.
Bears Say
Persistent Net LossesCordlife is still generating substantial net losses, showing that its current revenue base does not cover the full cost of operating the business. Continued losses can erode equity, restrict investment capacity, and delay the point at which its storage model produces dependable shareholder returns.
Negative Free Cash FlowNegative operating and free cash flow means the business is not currently funding itself through operations. Although cash burn has improved from 2024, continued outflows could gradually pressure liquidity and force Cordlife to use its balance-sheet resources before the operating turnaround is complete.
Weak Revenue TrajectoryModest revenue growth combined with a level still below earlier years points to a constrained top-line recovery. This limits operating leverage, makes fixed infrastructure costs harder to absorb, and increases the execution burden required to convert stabilization into sustainable profitability.
Cordlife Group News
P8A FAQ
What was Cordlife Group Limited’s price range in the past 12 months?
Cordlife Group Limited lowest share price was S$0.10 and its highest was S$0.27 in the past 12 months.
What is Cordlife Group Limited’s market cap?
Cordlife Group Limited’s market cap is S$30.89M.
When is Cordlife Group Limited’s upcoming earnings report date?
Cordlife Group Limited’s upcoming earnings report date is Nov 06, 2026 which is in 24 days.
How were Cordlife Group Limited’s earnings last quarter?
Cordlife Group Limited released its earnings results on Aug 13, 2026. The company reported -S$0.004 earnings per share for the quarter.
Is Cordlife Group Limited overvalued?
According to Wall Street analysts Cordlife Group Limited’s price is currently Overvalued.
Does Cordlife Group Limited pay dividends?
Cordlife Group Limited pays a Annually dividend of S$0.009 which represents an annual dividend yield of 2.5%. See more information on Cordlife Group Limited dividends here
What is Cordlife Group Limited’s EPS estimate?
Cordlife Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cordlife Group Limited have?
Cordlife Group Limited has 267,525,360 shares outstanding.
What happened to Cordlife Group Limited’s price movement after its last earnings report?
Cordlife Group Limited reported an EPS of -S$0.004 in its last earnings report. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Cordlife Group Limited?
Currently, no hedge funds are holding shares in SG:P8A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cordlife Group Limited
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
―